• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

    8/29/23 8:00:00 AM ET
    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNLI alert in real time by email

    CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as Growth Partner. In this role, he will help scale and grow several Flagship-founded companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development.

    David Khougazian

    Khougazian joins Flagship from Sanofi where he spent over two decades most recently leading Sanofi's engagement in global emerging markets including China, Eurasia, Latin America, and the Middle East. He also served as the CEO of Sanofi Pasteur MSD, a joint venture between Sanofi and Merck, and was previously Chief of Staff to the Sanofi CEO, leading the company's Transformation Office and serving as a member of the Executive Committee and Global Leadership Team. Prior to joining Sanofi, he was Vice President and Head of Mergers and Acquisitions at Aventis Pharmaceuticals and started his career at HSBC where he managed a portfolio of diversified financial assets.

    "David has deep experience developing and advancing healthcare companies by harnessing innovation partnerships," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. "I am pleased to welcome David to our team to help progress our companies as they create value and growth."

    "I am excited to join Flagship Pioneering and its growing ecosystem in revolutionizing the innovation process in health and developing platforms to address huge patient need," said David Khougazian, Growth Partner, Flagship Pioneering. "As part of Flagship's leadership team, I look forward to applying my experience in biopharma to scaling and growing Flagship's innovative bioplatform companies."

    About David Khougazian

    David brings more than 25 years of leadership experience in the global healthcare industry including over two decades at Sanofi where he held a diverse set of responsibilities during his tenure. He most recently led Sanofi's work in global emerging markets including China, Eurasia, Latin America and the Middle East. He also served as the CEO of Sanofi Pasteur MSD, a joint venture between Sanofi and Merck, and was previously Chief of Staff to the Sanofi CEO, leading Sanofi's Transformation Office and serving as a member of the Executive Committee and Global Leadership Team.

    Prior to joining Sanofi, David was Vice President and Head of Mergers and Acquisitions at Aventis Pharmaceuticals, a company he participated in creating as part of his finance and corporate development work at Rhône-Poulenc. David started his career at HSBC where he managed a portfolio of diversified financial assets.

    David is an engineer by training and graduated from ENSAE and holds an MBA from the Collège des Ingénieurs.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. To date, Flagship has deployed over $3.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $26 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 44 transformative companies, including Denali Therapeutics (NASDAQ:DNLI), Foghorn Therapeutics (NASDAQ:FHTX), Generate Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB) and Tessera Therapeutics.

    CONTACT: press@flagshippioneering.com

    (PRNewsfoto/Flagship Pioneering)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-announces-appointment-of-david-khougazian-as-growth-partner-301911946.html

    SOURCE Flagship Pioneering

    Get the next $DNLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNLI
    $FHTX
    $MCRB
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Denali Therapeutics Inc.
    $DNLI
    7/13/2026$29.00Overweight
    Analyst
    Seres Therapeutics Inc.
    $MCRB
    6/23/2026$12.00Buy
    H.C. Wainwright
    Sana Biotechnology Inc.
    $SANA
    5/11/2026$16.00Buy
    Rodman & Renshaw
    Denali Therapeutics Inc.
    $DNLI
    3/26/2026$32.00 → $42.00Buy
    H.C. Wainwright
    Denali Therapeutics Inc.
    $DNLI
    2/24/2026Peer Perform
    Wolfe Research
    Foghorn Therapeutics Inc.
    $FHTX
    2/17/2026$12.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    More analyst ratings

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    SEC Filings

    View All

    SEC Form S-8 filed by Seres Therapeutics Inc.

    S-8 - Seres Therapeutics, Inc. (0001609809) (Filer)

    7/9/26 4:05:28 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seres Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Seres Therapeutics, Inc. (0001609809) (Filer)

    7/8/26 4:05:18 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seres Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Seres Therapeutics, Inc. (0001609809) (Filer)

    7/8/26 8:00:09 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

    4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    2/12/24 5:46:20 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on Denali Therapeutics with a new price target

    Analyst resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $29.00

    7/13/26 9:07:21 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Seres Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Seres Therapeutics with a rating of Buy and set a new price target of $12.00

    6/23/26 8:25:58 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Sana Biotechnology with a new price target

    Rodman & Renshaw initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $16.00

    5/11/26 8:07:57 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

    Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseasesDenali is advancing multiple investigational therapies designed to cross blood-brain barrier for Alzheimer’s disease, including DNL628 (OTV:MAPT) targeting tau and DNL921 (ATV:Abeta) targeting amyloid beta SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the opening ple

    7/9/26 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

    Issued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /CNW/ -- USA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the fast-emerging field of longevity biology, developers are racing to turn engineered and donor-derived cells into durable, manufacturable therapies, and the companies that reach GMP-grade production first are the ones the market takes seriously. That i

    7/8/26 9:00:00 AM ET
    $ELDN
    $NCEL
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

    80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) SER-155 has potential to treat irEC, a frequent side effect of immune checkpoint inhibitors (ICIs) that often causes halting of cancer treatment, without requiring treatment with systemic immunosuppressive drugs SER-155 was well tolerated, with no drug-related serious adverse events observed Drug pharmacology data provide confirmatory evidence of Seres’ live biotherapeutics operating as designed to repair the mucosal epithelial barrier and reduce gastrointestinal inf

    7/8/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    7/16/26 4:45:38 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mcdonnell Michael R.

    4 - Moderna, Inc. (0001682852) (Issuer)

    7/10/26 5:08:03 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Mcdonnell Michael R.

    3 - Moderna, Inc. (0001682852) (Issuer)

    7/10/26 5:05:44 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

    CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy. The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. The webcast will occur on July 8, 2026, at 8:30 am ET. T

    6/25/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

    First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin receptor to cross blood-brain barrierDenali's first medicine enabled by its TransportVehicle™ platform designed to deliver biotherapeutics to whole body, including brainRare Pediatric Disease Priority Review Voucher (PRV) awarded in connection with FDA approvalDenali to host conference call and webcast today at 12:30 p.m. Eastern time SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the U.S. Food and Drug Adm

    3/25/26 11:50:28 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

    Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program

    3/2/26 4:05:00 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

    80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) SER-155 has potential to treat irEC, a frequent side effect of immune checkpoint inhibitors (ICIs) that often causes halting of cancer treatment, without requiring treatment with systemic immunosuppressive drugs SER-155 was well tolerated, with no drug-related serious adverse events observed Drug pharmacology data provide confirmatory evidence of Seres’ live biotherapeutics operating as designed to repair the mucosal epithelial barrier and reduce gastrointestinal inf

    7/8/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

    Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours. Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1 inhibitor, dencatis

    7/1/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

    Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Announced positive clinical results at 14 months from ongoing clinical trial transplanting UP421 without any immunosuppression into a patient with type 1 diabetes, showing ongoing survival and function Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Will prese

    5/11/26 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care